James P. Agalloco - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

James P. Agalloco


James P. Agalloco Pharmtech editorial advisory board (EAB) member

James P. Agalloco
President,
Agalloco & Associates

Agalloco is a past president of the Parenteral Drug Association (PDA) and served as an officer or director of PDA from 1982 to 1993. He has authored or co-authored more than 90 papers and lectured extensively on sterilization, aseptic processing, and validation at various PDA, PMA, the International Society for Pharmaceutical Engineering (ISPE), and Pharmaceutical Technology meetings, domestically as well as internationally. He is a member of USP’s Microbiology and Sterility Assurance Expert Committee for 2005–2010. Agalloco is a member of the editorial advisory boards of Pharmaceutical Technology and Pharmaceutical Manufacturing, and serves on the scientific advisory boards of Laureate, MEDInstill, MODA, and IPS.

He is a frequent author and lecturer on the subject of sterilization, aseptic processing, and process validation.

James Agalloco is president of Agalloco & Associates, which provides a range of technical services to the pharmaceutical and biotechnology industry. Since the formation of the company in 1991, Agalloco has assisted more than 100 healthcare firms in a wide range of validation, automation and compliance areas. During his more than 35 years of industry experience, he has worked in organic synthesis, pharmaceutical formulation, pharmaceutical production, project and process engineering, validation and process automation during his career at Merck, Pfizer, Squibb and Bristol-Myers Squibb.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here